Advanced Parkinson's disease patients struggling with motor fluctuations and involuntary movements now have a less invasive alternative to brain surgery or complex intestinal procedures. Real-world clinical experience reveals how this approach could reshape treatment decisions for thousands facing debilitating symptoms.
Continuous subcutaneous foslevodopa/foscarbidopa infusion delivers steady medication levels through a small under-skin pump, offering comparable efficacy to established device-aided therapies like deep brain stimulation or intestinal gel infusions. The system's primary advantage lies in its reversibility and reduced surgical complexity compared to brain implants, while avoiding the gastrointestinal complications associated with intestinal gel delivery systems. However, skin-related adverse effects emerged as the predominant limitation, requiring careful patient selection and proactive management strategies.
This development represents a significant expansion of treatment options for advanced Parkinson's disease, a condition affecting over 10 million people worldwide. The subcutaneous approach fills a critical gap between oral medications that lose effectiveness over time and highly invasive surgical interventions. While deep brain stimulation remains the gold standard for many patients, not everyone qualifies due to cognitive decline, surgical risks, or personal preferences. The skin-delivered system offers particular value for patients seeking device-aided therapy without permanent surgical modifications. However, the technology's success hinges on addressing dermatological complications that could limit long-term adherence. This real-world evidence suggests the therapy may be most suitable for patients with good skin integrity who require continuous medication delivery but wish to avoid surgical procedures. The approach may ultimately democratize access to advanced Parkinson's treatments by reducing procedural barriers.